https://scholars.lib.ntu.edu.tw/handle/123456789/551056
標題: | Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis | 作者: | TUNG-HUNG SU Peng C.-Y TAI-CHUNG TSENG HUNG-CHIH YANG CHUN-JEN LIU CHEN-HUA LIU PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2020 | 出版社: | Oxford University Press | 卷: | 221 | 期: | 4 | 起(迄)頁: | 589-597 | 來源出版物: | Journal of Infectious Diseases | 摘要: | Background: To investigate serum Mac-2-binding protein glycosylation isomer (M2BPGi) levels in predicting hepatocellular carcinoma (HCC) and mortality at virological remission (VR, HBV DNA <20 IU/mL) following antiviral therapy in chronic hepatitis B (CHB) patients with cirrhosis. Methods: This retrospective cohort study included patients with CHB-related Child-Pugh A cirrhosis undergoing long-term antiviral therapy. Serum M2BPGi levels were quantified and multivariable Cox proportional hazards regression models were used to identify risk predictors for HCC and death. Results: A total of 126 and 145 patients were included in the derivation and validation cohorts, respectively. The mean age was 56, and the mean M2BPGi level was 1.86 cut-off index (COI) in the derivation cohort. After adjustment for confounders, a higher M2BPGi level at VR significantly predicted HCC (hazard ratio [HR]: 1.58, 95% confidence interval [CI]: 1.19-2.10, P=0.002) and death (HR: 2.17, 95% CI: 1.02-4.62, P=0.044). The M2BPGi ?3 COI significantly increased the risk of HCC and death in the derivation and validation cohorts. Serial M2BPGi levels declined significantly (P=0.0001) in non-HCC patients only, and remained significantly lower than those who developed HCC afterwards (P=0.039). Conclusions: Serum M2BPGi levels at antiviral therapy-induced VR predict HCC development and death in patients with CHB-related Child-Pugh A cirrhosis. ? 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079020620&doi=10.1093%2finfdis%2fjiz496&partnerID=40&md5=aae4a8ef64f7ccb053dca5b5ed470316 https://scholars.lib.ntu.edu.tw/handle/123456789/551056 |
ISSN: | 0022-1899 | DOI: | 10.1093/infdis/jiz496 | SDG/關鍵字: | adefovir; entecavir; glycoprotein; lamivudine; Mac 2 binding protein glycosylation isomer; telbivudine; tenofovir; unclassified drug; antivirus agent; membrane protein; TAA90K protein, human; tumor antigen; tumor marker; adult; antiviral therapy; Article; cancer growth; cancer risk; Child Pugh score; chronic hepatitis B; cohort analysis; disease association; female; human; liver cell carcinoma; liver cirrhosis; long term care; major clinical study; male; middle aged; mortality; prediction; priority journal; protein analysis; protein blood level; protein function; remission; retrospective study; aged; blood; chronic hepatitis B; complication; glycosylation; Hepatitis B virus; liver cell carcinoma; liver cirrhosis; liver tumor; prognosis; remission; risk; virology; Adult; Aged; Antigens, Neoplasm; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Glycosylation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Risk |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。